146 related articles for article (PubMed ID: 35992118)
21. Characterization of the genomic alterations in poorly differentiated thyroid cancer.
Lee Y; Moon S; Seok JY; Lee JH; Nam S; Chung YS
Sci Rep; 2023 Nov; 13(1):19154. PubMed ID: 37932340
[TBL] [Abstract][Full Text] [Related]
22. Deciphering pathological behavior of pediatric medullary thyroid cancer from single-cell perspective.
Chen DQ; Zhou EQ; Chen HF; Zhan Y; Ye CJ; Li Y; Dai SY; Wang JF; Chen L; Dong KR; Dong R
PeerJ; 2023; 11():e15546. PubMed ID: 37744240
[TBL] [Abstract][Full Text] [Related]
23. Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma.
Boudin L; Morvan JB; Thariat J; Métivier D; Marcy PY; Delarbre D
Curr Oncol; 2022 Oct; 29(10):7718-7731. PubMed ID: 36290887
[TBL] [Abstract][Full Text] [Related]
24. Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report.
Goh D; Lim KH; Sudirman SRB; Ang MK; Chua MLK; Lim CM
Chin Clin Oncol; 2023 Oct; 12(5):57. PubMed ID: 37964542
[TBL] [Abstract][Full Text] [Related]
25. What is the status of immunotherapy in thyroid neoplasms?
Garcia-Alvarez A; Hernando J; Carmona-Alonso A; Capdevila J
Front Endocrinol (Lausanne); 2022; 13():929091. PubMed ID: 35992118
[TBL] [Abstract][Full Text] [Related]
26. What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?
Garcia-Alvarez A; Cubero JH; Capdevila J
Curr Oncol Rep; 2022 Apr; 24(4):451-461. PubMed ID: 35171460
[TBL] [Abstract][Full Text] [Related]
27. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
Ahn J; Jin M; Song E; Ryu YM; Song DE; Kim SY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Thyroid; 2021 Jan; 31(1):61-67. PubMed ID: 32611231
[No Abstract] [Full Text] [Related]
28. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
Cantara S; Bertelli E; Occhini R; Regoli M; Brilli L; Pacini F; Castagna MG; Toti P
Endocrine; 2019 Apr; 64(1):122-129. PubMed ID: 30762153
[TBL] [Abstract][Full Text] [Related]
29. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ndishabandi D; Ashry T; McCarthy M; Zhou Z; Amin S; Freeman GJ; Alessandrini A; Parangi S
Br J Cancer; 2018 Nov; 119(10):1223-1232. PubMed ID: 30327563
[TBL] [Abstract][Full Text] [Related]
30. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
31. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.
Capdevila J; Awada A; Führer-Sakel D; Leboulleux S; Pauwels P
Cancer Treat Rev; 2022 May; 106():102380. PubMed ID: 35305441
[TBL] [Abstract][Full Text] [Related]
32. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
[TBL] [Abstract][Full Text] [Related]
33. Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy.
Hao Z; Li R; Wang Y; Li S; Hong Z; Han Z
Biomark Res; 2021 Oct; 9(1):77. PubMed ID: 34689842
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 Expression in Medullary Thyroid Carcinoma and Its Association with Clinicopathological Findings.
Kemal Y; Çalişkan S; Gun S; Kefeli M
Turk Patoloji Derg; 2022; 38(2):106-113. PubMed ID: 34580845
[TBL] [Abstract][Full Text] [Related]
35. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
